Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk Ventilation -4% Progression 12% primary Menichetti et al. NCT04716556 TSUNAMI Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 471 patients in Italy (July - December 2020) Lower mortality (p=0.47) and progression (p=0.54), not stat. sig. Menichetti et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.36246 Favors conv. plasma Favors control
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia
Menichetti et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.36246, TSUNAMI, NCT04716556 (history)
Menichetti et al., Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized.., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.36246, TSUNAMI, NCT04716556
Nov 2021   Source   PDF  
  All Studies   Meta
RCT 487 patients in Italy, showing no significant difference in outcomes with convalescent plasma.
risk of death, 23.4% lower, RR 0.77, p = 0.47, treatment 14 of 231 (6.1%), control 19 of 240 (7.9%), NNT 54.
risk of mechanical ventilation, 3.9% higher, RR 1.04, p = 1.00, treatment 25 of 231 (10.8%), control 25 of 240 (10.4%), mechanical ventilation or death.
risk of progression, 12.0% lower, RR 0.88, p = 0.54, treatment 59 of 231 (25.5%), control 67 of 239 (28.0%), NNT 40, PaO2/FiO2 <150 mm Hg or death, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Menichetti et al., 29 Nov 2021, Randomized Controlled Trial, Italy, peer-reviewed, 110 authors, study period 15 July, 2020 - 8 December, 2020, average treatment delay 7.0 days, trial NCT04716556 (history) (TSUNAMI).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: Original Investigation | Infectious Diseases Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia A Randomized Clinical Trial Francesco Menichetti, MD; Patrizia Popoli, MD; Maria Puopolo, MS; Stefania Spila Alegiani, MS; Giusy Tiseo, MD; Alessandro Bartoloni, MD; Giuseppe Vittorio De Socio, MD; Sauro Luchi, MD; Pierluigi Blanc, MD; Massimo Puoti, MD; Elena Toschi, MS; Marco Massari, MS; Lucia Palmisano, MS; Giuseppe Marano, MD; Margherita Chiamenti, MD; Laura Martinelli, MD; Silvia Franchi, MD; Carlo Pallotto, MD; Lorenzo Roberto Suardi, MD; Barbara Luciani Pasqua, MD; Marco Merli, MD; Plinio Fabiani, MD; Luca Bertolucci, MD; Beatrice Borchi, MD; Sara Modica, MD; Sara Moneta, MD; Giulia Marchetti, MD; Antonella d’Arminio Monforte, MD; Laura Stoppini, MD; Nadia Ferracchiato, MD; Stefania Piconi, MD; Claudio Fabbri, MD; Enrico Beccastrini, MD; Riccardo Saccardi, MD; Andrea Giacometti, MD; Sara Esperti, MD; Piera Pierotti, MD; Laura Bernini, MD; Claudia Bianco, MD; Sara Benedetti, MD; Alessandra Lanzi, MD; Paolo Bonfanti, MD; Marco Massari, MD; Spartaco Sani, MD; Annalisa Saracino, MD; Antonella Castagna, MD; Luigia Trabace, PhD; Maria Lanza, MD; Daniele Focosi, MD; Alessandro Mazzoni, MD; Mauro Pistello, MD; Marco Falcone, MD; for the TSUNAMI Study group Abstract Key Points IMPORTANCE Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia. Question Is convalescent plasma useful in preventing worsening respiratory failure or death in patients with OBJECTIVE To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing COVID-19 pneumonia? Findings In this randomized clinical trial worsening respiratory failure or death in patients with COVID-19 pneumonia. of 487 patients with COVID-19 DESIGN, SETTING, AND PARTICIPANTS This prospective, open-label, randomized clinical trial pneumonia and a partial pressure of enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone arterial oxygen–to–fraction of inspired between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 oxygen (PaO2/FiO2) ratio between 350 pneumonia and a partial pressure of oxygen–to–fraction of inspired oxygen (PaO2/FiO2) ratio between and 200 mm Hg at enrollment, the rate 350 and 200 mm Hg were eligible. of the primary clinical end point (need for mechanical ventilation, defined as INTERVENTIONS Patients in the experimental group received intravenous high-titer CP (ⱖ1:160, by PaO2/FiO2 ratio <150 mm Hg, or death) microneutralization test) plus ST. The volume of infused CP was 200 mL given from 1 to a maximum was not significantly different between of 3 infusions. Patients in the control group received ST, represented by remdesivir, glucocorticoids, the convalescent plasma group and the and low–molecular weight heparin, according to the Agenzia Italiana del Farmaco recommendations. control group. Meaning In this trial, convalescent MAIN OUTCOMES AND MEASURES The primary outcome was a composite of worsening plasma did not reduce the progression respiratory failure (PaO2/FiO2 ratio <150 mm Hg) or death within 30 days from randomization. to severe respiratory failure or death within 30 days. RESULTS Of the 487 randomized patients (241 to CP plus ST;..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop